Search - tctmd.com

Displaying 321 - 340 of 7110

Sort: Relevancy | Date

Presentation TCT 2016

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Michael Argenziano, Alec S. Vahanian, Daniel Burkhoff

October 31, 2016

Presentation TCT 2016

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo

October 31, 2016

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Presentation TCT 2016

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Michael Haude

October 31, 2016

Presentation TCT 2016

Rationale for and Design of GALILEO

Presenter: Michael Argenziano, Alec S. Vahanian, Paul Sorajja

October 31, 2016

Presentation TCT 2016

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Alexandre Abizaid

October 31, 2016

News Industry News

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

October 31, 2016

Presentation TCT 2016

B Braun - ISAR Coroflex

Presenter: Marie-Claude Morice, Christian Hengstenberg

October 31, 2016

Presentation TCT 2016

FAME I and FAME II: Predictive Value of Fractional Flow Reserve After Drug-Eluting Stent Implantation

Presenter: Spencer B. King III, Jagat Narula, Zsolt Piroth

October 31, 2016

Presentation TCT 2016

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Jo Simonsen

October 31, 2016

Presentation TCT 2016

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Jo Simonsen

October 31, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Stephen G. Worthley

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

Alvimedica - Cre8: Design Specifications and Results

Presenter: Marie-Claude Morice, Gennaro Sardella

October 31, 2016

Presentation TCT 2016

Biosensors Biofreedom/Cordis Lumeno: Angiographic/Clinical Outcomes And Further Worldwide Development Strategy

Presenter: Marie-Claude Morice, Philip M. Urban

October 31, 2016

Presentation TCT 2016

Medtronic Drug-Filled Stent: 6-Month Results From Revelution

Presenter: Marie-Claude Morice, Stephen G. Worthley

October 31, 2016

Presentation TCT 2016

TCT 442: 3-Year Clinical Outcomes of Complete Versus Partial Stent Fracture After Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stent

Presenter: Nicolas Foin, Giampaolo Niccoli

October 31, 2016

News Industry News

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

Advertisement

Rationale for and Design of TAVR UNLOAD: What I Expect the Findings to Be But What Wont Surprise Me!

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Rationale for and Design of GALILEO

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

B Braun - ISAR Coroflex

FAME I and FAME II: Predictive Value of Fractional Flow Reserve After Drug-Eluting Stent Implantation

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

TCT 29: Performance and Healing Patterns After Implantation of a Novel Sirolimus-Eluting Bioresorbable Scaffold. Six-Month Follow-Up by Optical Coherence Tomography in the FANTOM II Study

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

REVELUTION: Nine-Month Clinical, Angiographic, IVUS, and OCT Outcomes With a Polymer-Free Sirolimus-Eluting Drug-Filled Stent

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Alvimedica - Cre8: Design Specifications and Results

Biosensors Biofreedom/Cordis Lumeno: Angiographic/Clinical Outcomes And Further Worldwide Development Strategy

Medtronic Drug-Filled Stent: 6-Month Results From Revelution

TCT 442: 3-Year Clinical Outcomes of Complete Versus Partial Stent Fracture After Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stent

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content